



Opening: Christian Doppler Laboratory for Immunometabolism and Systems Biology of Obesity-Related Diseases (InSpiReD)

Thursday, 17th November 2022, 9.00 a.m.

Rektoratssaal, MedUni Vienna
Spitalgasse 23, 1090 Vienna

www.meduniwien.ac.at/cdlab-immunometabolism

Opening: Christian Doppler Laboratory for Immunometabolism and Systems Biology of Obesity-Related Diseases (InSpiReD)

One of the main focuses of the new Christian Doppler laboratory is macrophages and how clearance of dead/dying cells (also called „efferocytosis“) reprograms their immune-metabolic landscape.

Defects in efferocytosis occur in obesity related diseases and are associated with inflammation and tissue damage. Which leads to the question of: What do obesity-associated and efferocytosing macrophages have in common and what are the consequences therein for disease?

These are some of the key questions addressed in this new CD laboratory with the aim of identifying potential new pathways altered in disease.



In **Christian Doppler Laboratories**, application-oriented basic research is carried out at a high level, with outstanding scientists cooperating with innovative companies. For the promotion of this cooperation, the Christian Doppler Research Association is internationally regarded as an example of best practice.

 **Federal Ministry
Republic of Austria**
Labour and Economy

Christian Doppler Laboratories are jointly funded by the public sector and the participating companies. The most important public funding body is the Federal Ministry Republic of Austria Labour and Economy.



Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Understanding the role of immune metabolism in human diseases triggered the collaboration with the CD Laboratory for Immunometabolism and Systems Biology of Obesity-Related Diseases, with the aim to identify novel therapeutic starting points for Boehringer Ingelheim's drug discovery.

Thursday, 17th November 2022,
9.00 a.m.
Rektoratssaal
MedUni Vienna

Programme

Welcome

Michaela Fritz, Vice Rector for Research and Innovation
of the Medical University Vienna

Martin Gerzabek, President of the Christian Doppler
Research Association

Presentation of the Christian Doppler Laboratory

Omar Sharif
Principal Investigator, Medical University of Vienna

Thomas Reiberger
Professor of Gastroenterology and Hepatology,
Medical University of Vienna

Eric Borges
Vice President, Cancer Immunology & Immune
Modulation, Boehringer Ingelheim

Kerstin Kitt
Director Immune Modulation, Boehringer Ingelheim

Moderation:
Thomas Weichhart, Professor of Medical Genetics,
Medical University Vienna

Get-together

Please register until 10th November 2022 under
www.meduniwien.ac.at/cdlab-immunometabolism



Rektoratssaal, Rektoratsgebäude (BT88), Floor 01
Medical University of Vienna
Spitalgasse 23, 1090 Vienna

We recommend wearing an FFP2 mask during the event. Covid positive tested individuals are not allowed to participate in the event. The measures may change according to the pandemic situation, the current rules are published on the website www.meduniwien.ac.at/cdlab-inspired

Please be aware that photographs and/or video footage will be taken at the event. These may be used for the purpose of documenting or reporting the event and published in print and online media, on various social media platforms and on MedUni Vienna's website.